Piramal Pharma - Work-In-Progress To Address Challenges In The CDMO Segment: Motilal Oswal
While there are near-term headwinds in its CDMO business, the outlook remains interesting.
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
As a demerged entity, Piramal Pharma Ltd. reported its first quarter of detailed financials. The receipts from government grants have been included in other income and excluded from Ebitda and hence it is not comparable with our Ebitda estimate.
Including other income, Ebitda stood at Rs 2.2 billion (our estimate: Rs 2.3 billion). The moderate YoY growth in sales and increased opex affected profitability on a YoY basis.
We have recalibrated Piramal Pharma's FY23/FY24 earnings estimate based on:
its detailed financials,
prolonged period of pandemic-induced challenges in the contract development and manufacturing organisation business, and
improved traction in the complex hospital generics and the India consumer products segment.
Click on the attachment to read the full report:
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.